We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Long-Read DNA Test Improves Diagnosis of Rare Genetic Diseases

By LabMedica International staff writers
Posted on 15 Jun 2026

Rare diseases affect up to 400 million people worldwide, yet many remain difficult to diagnose and often require years-long diagnostic journeys. More...

Approximately 80% have a genetic basis, but conventional tests analyze the genome in fragments and can miss complex variants. These limitations can delay care planning and family risk assessment across more than 7,000 conditions. A new study shows that a comprehensive long-read DNA test increases diagnostic yield and could streamline the diagnostic workup.

Radboud University Medical Center (Radboudumc; Nijmegen, Netherlands) and Maastricht University Medical Center+ (Maastricht UMC+) evaluated a long-read genome sequencing test alongside current standard diagnostics in 1,000 patients. The team found the approach delivered additional answers and could simplify multi-test pathways for rare genetic disorders. Writing in The New England Journal of Medicine, the researchers recommend that this test be adopted everywhere as the first-choice diagnostic.

The method reads DNA in much larger segments—up to 20,000 building blocks—compared with today’s typical fragment length of about 300. Like assembling a jigsaw puzzle, using larger pieces makes reconstruction easier and yields a more complete picture of the genome. The test also measures modifications on the outside of DNA that can switch genes on or off, capturing information that otherwise requires extra specialized tests.

In the head-to-head comparison, the new test produced 3% more diagnoses than standard workflows. It can also replace 15 other tests, reducing the need for multiple procedures while improving diagnostic efficiency. The number of diagnoses is expected to continue rising as more complex and difficult-to-detect abnormalities are linked to specific conditions.

Use of long-read sequencing was further highlighted at the recent Undiagnosed Hackathon in Nijmegen. Nearly 150 specialists from all Dutch university medical centers analyzed 33 families, and the long-read approach mapped each family’s DNA in detail. The effort resulted in five new diagnoses, underscoring the test’s ability to reveal clinically relevant findings.

“We showed that the new test yields 3% more diagnoses. It can also replace 15 other tests. We recommend using this test worldwide as the first choice,” said Lisenka Vissers, Professor of Translational Genomics at Radboud University.

“Thanks to long reads, we obtain an even more complete view of DNA and can detect complex and hard-to-find abnormalities. We then link these to specific conditions. In this way, our knowledge grows and we can make more diagnoses,” said Alexander Hoischen, Professor of Genomic Technologies at Radboud University.

Related Links
Radboudumc
Maastricht UMC+


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.